https://www.sandoz.comhttp://spare53_sandoz_com/
2024-03-06T13:43:26+00:00
daily
1.0
https://www.sandoz.comhttp://spare53_sandoz_com/corporate-governance
2023-08-11T13:27:38+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-cookies-sandoz-web-sites
2023-09-13T14:48:35+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/error-404
2023-12-04T12:55:30+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/terms-use-and-conditions
2023-10-02T20:19:02+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/website-privacy-policy
2023-09-13T03:17:41+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-privacy-hub
2023-10-02T14:21:36+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/privacy/general-privacy-notice-business-partners
2023-09-07T15:21:05+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/privacy/general-privacy-notice-third-parties
2023-09-07T15:31:00+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/privacy/sandoz-data-privacy-notice-job-prospects-and-candidates
2023-09-07T15:41:18+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/estonia-supplier-privacy-notice
2023-09-12T13:42:34+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/estonia-hcp-privacy-notice
2023-09-12T13:52:25+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/philippines-privacy-notice
2023-09-12T22:21:08+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/israel-privacy-notice-suppliers
2023-09-12T13:53:33+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/israel-privacy-notice-business-partners
2023-09-12T13:57:41+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/poland-privacy-notice-stakeholders
2023-09-12T00:48:47+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/israel-privacy-notice-pharmacovigilance-medical-information-and-product-quality-complaints
2023-09-12T14:02:43+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/latvia-privacy-notice-suppliers
2023-09-12T14:07:25+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/latvia-privacy-notice-business-partners
2023-09-12T14:10:44+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/lithuania-privacy-notice-suppliers
2023-09-12T14:33:43+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/lithuania-privacy-notice-business-partners
2023-09-12T14:37:03+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/poland-privacy-notice-suppliers
2023-09-12T00:51:06+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/poland-privacy-notice-business-partners
2023-09-12T00:49:47+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/poland-privacy-notice-pharmacovigilance-medical-information-and-product-quality-complaints
2023-09-12T22:13:58+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/poland-website-privacy-notice
2023-09-12T00:44:22+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/thailand-privacy-notice
2023-09-12T07:34:21+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/privacy/privacy-notice-pharmacovigilance-medical-information-and-product-quality-complaints
2023-09-12T11:42:28+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/latvia-privacy-notice-pharmacovigilance-medical-information-and-product-quality-complaints
2023-09-12T14:24:44+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/controller-processor
2023-09-12T06:09:05+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/controller-controller
2023-09-12T06:49:31+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/minimum-information-security-controls-third-parties
2023-09-12T07:16:18+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/lithuania-pv-privacy-notice
2023-09-12T08:23:40+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/estonia-pv-privacy-notice
2023-09-12T09:09:02+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/privacy/general-privacy-notice-clinical-trial-site-personnel
2023-09-12T11:17:52+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/supplier-portal/documentation
2023-11-02T11:24:00+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/antimicrobial-resistance-five-essential-steps-help-avert-global-health-crisis
2023-10-17T09:25:28+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/act4biosimilars-enabling-greater-uptake-biosimilars-improve-health-equity
2023-10-27T13:16:59+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/biosimilars-democratizing-access-innovative-medicines
2023-11-01T10:10:48+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-legacy-pioneering-access-patients
2023-11-01T10:23:29+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/streamline-harmonize-how-improve-access-biosimilars
2023-11-03T14:14:05+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/xxvcareers
2023-09-12T00:04:47+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/living-multiple-sclerosis-ms
2023-06-29T19:44:06+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-spin
2023-10-03T13:03:49+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/node/586
2024-03-06T13:43:26+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/investors
2023-07-25T10:06:10+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/pplcul/peo11ple-culture
2023-09-29T11:08:13+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-plans-joint-investment-help-strengthen-future-antibiotics-manufacturing-europe
2023-06-27T12:00:04+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/test-kaltura-page
2023-10-16T12:56:52+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/careers/career-search
2023-06-21T05:27:05+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/news/media-library
2023-06-22T08:02:56+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/corporate-calendar
2023-07-25T14:51:03+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/-do-not-useimpact
2023-09-19T15:53:43+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/code-of-conduct
2023-09-29T16:55:56+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/board-directors
2023-10-17T18:48:01+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture
2023-09-29T12:37:25+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/corporate-assurance/ethics-compliance
2023-11-08T12:56:26+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/corporate-assurance/corporate-security
2023-10-01T13:52:42+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/corporate-assurance/health-safety-environment
2023-10-01T14:30:28+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/corporate-assurance
2023-10-31T08:37:51+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/corporate-assurance/speakup
2023-10-01T16:59:34+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/impact
2024-03-14T08:43:08+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/careers/job-search
2023-09-19T17:25:34+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/corporate-assurance/thired-party-risk-management
2023-11-09T08:57:24+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/sandoz-leadership
2023-12-01T08:15:03+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/impact/access
2024-03-14T08:50:31+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/careers
2024-02-16T14:09:54+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/media/news
2023-09-22T19:13:51+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/board-directors/gilbert-ghostine
2023-09-11T23:56:20+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/board-directors/dr-karen-j-huebscher
2023-09-11T23:59:21+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/board-directors/francois-xavier-roger
2023-09-11T23:56:39+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/board-directors/urs-riedener
2023-09-11T23:58:57+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/board-directors/dr-shamiram-r-feinglass
2023-09-20T10:15:19+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/board-directors/aarti-shah-phd
2023-09-11T23:58:01+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/board-directors/yannis-skoufalos
2023-09-11T23:57:38+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/board-directors/remco-steenbergen
2023-09-11T23:57:10+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/board-directors/maria-varsellona
2023-09-14T12:47:50+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/pioneers-and-progress
2023-10-01T12:25:48+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/sandoz-leadership/richard-saynor
2023-10-02T14:57:11+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/sandoz-leadership/francisco-ballester
2023-10-02T15:02:13+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/sandoz-leadership/pierre-bourdage
2023-09-25T05:59:55+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/what-we-do
2024-03-11T13:40:07+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/our-purpose-and-ambition
2024-01-17T14:41:35+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/company-overview
2023-09-22T20:58:45+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/corporate-assurance/integrated-assurance
2023-09-22T21:09:26+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/corporate-assurance/human-rights
2024-03-06T09:51:23+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/corporate-assurance/data-privacy
2023-09-30T13:47:48+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/sandoz-leadership/claire-dabreu-hayling
2023-09-25T06:06:07+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz
2023-10-03T10:06:50+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/sandoz-leadership/glenn-gerecke-phd
2023-09-25T06:06:41+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/sandoz-leadership/simon-goeller
2023-09-13T11:36:47+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/sandoz-leadership/rebecca-guntern
2023-09-25T06:07:07+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/business/business-to-business-b2b
2023-10-01T09:28:19+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/sandoz-leadership/keren-haruvi
2023-09-25T06:07:37+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/business/biosimilars/sandoz-biosimilar-pipeline
2024-03-11T15:21:14+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/sandoz-leadership/ingrid-sollerer
2023-09-25T06:09:05+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/sandoz-leadership/tripti-jha1
2023-09-14T14:09:21+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/sandoz-leadership/steffen-kurzawa
2023-09-25T06:08:45+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/sandoz-leadership/colin-bond
2023-09-25T05:59:36+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/business/biosimilars/biologics-bring-breakthroughs
2023-10-02T12:35:39+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/business/manufacturing-quality-and-supply
2023-09-30T22:29:40+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/business/biosimilars/science-expertise-innovation
2023-10-02T18:37:19+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/business/generics
2024-03-11T14:06:34+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/associate-stories
2023-09-30T23:04:35+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/contact
2023-10-02T12:17:03+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/impact/people
2023-10-01T10:22:37+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/impact/governance
2023-10-23T12:06:27+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/business/biosimilars/sandoz-biosimilar-portfolio
2024-03-12T16:06:24+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/careers/our-teams
2023-10-01T14:13:22+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/careers/our-teams/people-organization
2023-10-01T00:34:13+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/careers/flexible-hybrid-working
2024-01-18T14:04:28+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/careers/diversity-inclusion
2024-03-05T10:27:16+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/media
2024-03-12T12:50:31+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/impact/environment
2024-03-14T09:02:32+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/careers/rewards-recognition
2024-02-08T15:20:32+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/business/biosimilars/information-patients
2023-10-02T12:35:59+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/careers/our-teams/technology
2024-02-04T14:28:46+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/careers/personal-growth-learning-sandoz
2023-10-02T15:24:35+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/business/biosimilars/value-biosimilars
2023-10-02T12:35:20+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/careers/people-and-culture
2024-03-05T10:21:59+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/patients-and-caregivers
2023-10-02T18:42:57+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/ceo-corner
2023-10-01T02:29:19+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/media/stay-up-to-date
2023-09-22T23:01:15+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/business/biosimilars
2023-10-02T12:35:12+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-site-directory
2023-10-02T11:52:50+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/media/publications
2024-03-12T12:20:51+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/home
2023-09-22T16:23:42+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/business
2023-10-03T14:36:07+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/about-sandoz/company-overview/corporate-governance
2023-12-20T12:03:46+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/adverse-event-reporting
2023-10-02T13:52:43+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-external-funding
2023-09-25T05:04:22+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/news/news-archive
2023-09-28T06:58:06+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/impact/esg-faqs
2023-12-14T10:05:05+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/media/contact
2023-10-12T12:19:36+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/people-culture/sandoz-leadership/asaf-gal
2023-10-13T15:01:29+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/policies
2023-11-29T12:12:42+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/impact/access/key-partnerships
2024-03-12T09:06:54+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-receives-european-commission-approval-tyrukor-natalizumab-first-and-only-biosimilar-multiple
2023-10-17T09:40:56+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-confirms-sandoz-spin-october-4-2023-0
2023-10-02T09:37:54+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-receives-positive-chmp-opinion-breast-and-gastric-cancer-biosimilar-trastuzumab
2023-10-02T09:36:36+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-shareholders-approve-proposed-100-spin-sandoz
2023-10-02T09:36:07+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-exclusive-deal-commercialize-biosimilar-ustekinumab-further-reinforcing-growing
2023-10-02T09:35:28+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-publishes-supplement-listing-prospectus-including-sandoz-h1-2023-financial-statements
2023-10-18T18:23:43+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-completes-acquisition-leading-antifungal-agent-mycaminer-astellas-reinforcing-leading-global
2023-10-02T09:32:37+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-receives-fda-approval-tyrukor-natalizumab-sztn-first-and-only-fda-approved-biosimilar
2023-10-02T09:32:00+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-issues-egm-invitation-and-shareholder-information-brochure-sandoz-publishes-listing
2023-10-18T18:25:31+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-positive-results-mylight-phase-lll-study-biosimilar-aflibercept
2023-10-02T09:27:11+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-receives-positive-chmp-opinion-multiple-sclerosis-biosimilar-natalizumab
2023-10-02T09:26:36+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-plans-build-biosimilar-technical-development-center-slovenia-support-future-growth
2023-10-02T09:23:03+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-delivers-strong-sales-growth-robust-margin-expansion-and-raises-guidance-announces-usd-15
2023-10-18T18:26:49+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-launch-hyrimozr-adalimumab-adaz-high-concentration-formulation-marking-sandoz-entrance-us
2023-10-02T09:22:26+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-introduces-act4biosimilars-action-plan-accelerate-patient-access-biosimilar-medicines
2023-10-02T09:21:47+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-presents-compelling-investment-proposition-standalone-company-capital-markets-day
2023-10-02T09:18:13+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-plans-move-new-central-basel-headquarters-mid-2024-following-proposed-spin-standalone
2023-10-02T09:17:29+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-marketing-authorization-applications-proposed-biosimilar-denosumab-accepted-ema
2023-10-02T09:17:55+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/new-sandoz-board-directors-appointed
2023-10-02T09:19:15+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-strengthens-pipeline-expansion-through-partnership-develop-and-manufacture-multiple
2023-10-02T09:19:04+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-enters-new-era-standalone-global-leader-european-champion-in-generic-and-biosimilar-medicines
2023-10-18T18:22:25+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-developing-holzkirchen-site-leading-biopharma-technical-development-hub-support-future
2023-10-11T11:21:06+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-exclusively-commercialize-six-products-us-reinforcing-global-leadership-position-patent
2023-10-11T11:27:42+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-receives-approval-european-commission-hyrimozr-adalimumab-high-concentration-formulation
2023-10-11T11:29:25+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-receives-us-fda-approval-biosimilar-hyrimozr-adalimumab-adaz-high-concentration-formulation
2023-10-11T11:30:45+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-signs-memorandum-understanding-build-new-biologics-production-plant-slovenia-support
2023-10-11T11:32:00+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-announces-appointment-chairman-designate-sandoz-board-directors
2023-10-11T11:58:08+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-biologics-license-application-proposed-biosimilar-denosumab-accepted-us-fda
2023-10-11T11:59:27+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-continues-grow-further-core-margin-expansion-and-achieves-important-innovation-milestones
2023-10-18T18:30:06+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-ag-expands-reach-hyrimozr-adalimumab-adaz-us-through-commercialization-agreement-cordavis
2023-10-11T12:06:00+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-receives-positive-chmp-opinion-citrate-free-high-concentration-formulation-adalimumab
2023-10-11T12:07:13+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-agreement-acquire-leading-antifungal-agent-mycaminer-astellas-reinforcing-hospital
2023-10-11T12:08:19+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/study-shows-sandoz-employs-germanys-best-graduates
2023-10-11T12:09:51+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-further-investment-key-manufacturing-facility-austria-support-increased-global
2023-10-11T12:11:12+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-maintains-growth-momentum-and-confirms-fy22-group-guidance
2023-10-18T18:31:56+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-further-progress-its-biosimilar-pipeline-release-positive-results-denosumab
2023-10-11T12:13:44+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/applications-proposed-first-kind-multiple-sclerosis-biosimilar-natalizumab-accepted-us-fda-and-ema
2023-10-11T12:15:14+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-supplemental-biologics-license-application-accepted-us-fda-biosimilar-hyrimozr-adalimumab
2023-10-11T12:16:33+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-application-proposed-biosimilar-adalimumabs-high-concentration-formulation-accepted-ema
2023-10-11T12:17:47+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/hexal-launches-dimethyl-fumarate-hexalr-generic-drug-tecfiderar-germany-offering-economically
2023-10-11T12:18:50+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-new-global-act4biosimilars-initiative-improve-patient-access-and-increase-adoption
2023-10-11T12:19:59+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-appoints-new-board-representative-global-amr-industry-alliance
2023-10-11T12:21:07+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-launches-first-generic-pirfenidone-us-patients-idiopathic-pulmonary-fibrosis-growing-its
2023-10-11T12:22:26+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-delivers-solid-sales-and-profit-growth-strong-performance-market-brands-supports
2023-10-18T18:36:54+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-launches-generic-brimonidine-tartratetimolol-maleate-eyedrop-us-patients-ocular-hypertension
2023-10-11T12:25:19+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-extends-collaboration-agreement-drive-cutting-edge-digital-solutions-global-fight-against
2023-10-11T12:26:25+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-targets-growth-opportunities-respiratory-and-complex-generics-through-acquisition
2023-10-11T12:27:33+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-launches-generic-lenalidomide-19-countries-across-europe-expanding-access-essential-oncology
2023-10-11T12:28:42+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-delivers-mid-single-digit-sales-growth-margin-expansion-and-advancement-robust-pipeline
2023-10-18T18:38:28+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-submits-marketing-authorization-application-proposed-biosimilar-trastuzumab-ema
2023-10-11T12:31:15+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-submits-biologics-license-application-proposed-biosimilar-trastuzumab-us-fda
2023-10-11T12:32:31+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-signs-new-initial-agreement-biontech-support-fill-and-finish-mrna-pfizer-biontech-covid-19
2023-10-11T12:33:48+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-completes-acquisition-gsks-cephalosporin-business-reinforcing-leading-global-position
2023-10-11T12:35:08+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-resolves-legacy-federal-government-civil-investigation-us-regarding-generic-drugs
2023-10-11T12:37:00+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-strengthens-pipeline-entering-agreement-biosimilar-bevacizumab-key-oncology-medicine
2023-10-11T12:38:08+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-delivered-strong-q2-performance-driven-momentum-key-growth-brands-fy-2021-guidance
2023-10-18T18:41:33+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-launches-first-generic-high-dose-intravenous-iron-ferumoxytol-injection-treat-us-patients
2023-10-11T12:40:21+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-eu-launch-ready-dilute-generic-pemetrexed-treat-most-prevalent-form-lung-cancer
2023-10-11T12:41:24+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-plans-further-strengthen-its-antibiotics-manufacturing-setup-europe
2023-10-11T12:42:35+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/us-supreme-court-denies-sandoz-petition-review-biosimilar-erelzir-etanercept-szzs-case
2023-10-11T12:43:38+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-confirms-late-stage-clinical-development-plans-proposed-biosimilar-aflibercept-key
2023-10-11T12:44:39+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-licenses-brand-and-authorized-generic-respiratory-medicine-proventilr-hfa-albuterol-sulfate
2023-10-11T12:45:48+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-agreement-acquire-gsks-cephalosporin-antibiotics-business-reinforcing-its-leading
2023-10-11T12:46:48+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-officially-certified-global-top-employer-2021
2023-10-11T12:47:49+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-appoints-new-board-representative-global-amr-industry-alliance-0
2023-10-11T12:49:01+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-donates-20-critically-needed-generic-medicines-hospitals-and-dispensaries-continued-support
2023-10-11T12:49:56+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-launches-its-first-rfid-tagged-critical-injectable-medicines-kit-check-optimize-supply-chain
2023-10-11T12:50:59+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/new-collaboration-between-novartis-and-africa-medical-supplies-platform-facilitate-supply-covid-19
2023-10-11T12:51:58+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-plans-joint-investment-help-strengthen-future-antibiotics-manufacturing-europe-0
2023-10-11T12:53:01+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-launches-generic-antibiotic-daptomycin-us-strategically-growing-injectables-portfolio-and
2023-10-11T12:54:02+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-collaborates-civica-rx-help-reduce-critical-generic-medicine-shortages-us-hospitals
2023-10-11T12:54:57+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-reviewing-options-after-federal-circuit-upholds-lower-court-ruling-biosimilar-erelzir-case
2023-10-11T12:55:56+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-discontinues-hydroxychloroquine-clinical-trial-based-slow-enrollment-remains-committed
2023-10-11T12:56:53+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-launches-once-daily-generic-tacrolimus-transplant-patients-europe
2023-10-11T12:57:53+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-sponsor-large-clinical-trial-hydroxychloroquine-hospitalized-covid-19-patients
2023-10-11T12:58:51+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-donation-consignment-30-million-hydroxychloroquine-tablets-ships-us-department-health-and
2023-10-11T12:59:49+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-new-country-head-japan
2023-10-11T13:02:31+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-commits-donate-130-million-doses-hydroxychloroquine-support-global-covid-19-pandemic
2023-10-11T13:03:47+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-commits-keep-prices-stable-basket-essential-covid-19-medicines-novartis-responds-covid-19
2023-10-11T13:04:49+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-officially-recognized-global-top-employer-2020
2023-10-11T13:05:56+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-delivers-strong-sales-growth-robust-margin-expansion-and-major-innovation-milestones
2023-10-18T18:28:22+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-delivers-continued-strong-momentum-key-growth-brands-progress-strategic-initiatives-and
2023-10-18T18:35:02+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-key-growth-drivers-and-launches-continue-momentum-q1-maintaining-confidence-growth-group
2023-10-18T18:43:23+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-delivered-sales-growth-and-margin-expansion-continued-progress-its-next-wave-medicines
2023-10-18T18:44:49+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-delivers-solid-q3-performance-11-core-operating-income-growth-net-sales-line-prior-year
2023-10-18T18:46:18+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-delivered-strong-h1-performance-fy-2020-guidance-confirmed-higher-end-core-operating
2023-10-18T18:47:34+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-maintains-strong-operational-performance-q1-confirms-fy-2020-guidance-time-and-advances
2023-10-18T18:48:55+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-delivered-strong-sales-growth-margin-expansion-and-breakthrough-innovation-launching-five
2023-10-18T18:54:38+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-announces-mutual-agreement-terminate-sale-sandoz-us-generic-oral-solids-dermatology
2023-10-18T18:50:13+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-announces-intention-separate-sandoz-business-create-standalone-company-way-100-spin
2023-10-18T18:33:33+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/novartis-delivers-solid-q3-results-strong-growth-innovative-medicines-announces-strategic-review
2023-10-18T18:40:01+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-resolves-generic-drug-antitrust-investigation-us
2023-10-18T18:51:35+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-completes-acquisition-aspens-japanese-operations-strengthening-its-position-worlds-third
2023-10-18T18:52:55+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz_reports_year-to-date_sales_for_the_first_nine_months_of_2023
2023-10-26T09:15:32+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-successfully-issues-chf-750-million-inaugural-bonds
2023-10-26T15:50:14+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/who-igba-meeting-working-together-support-global-access-generic-and-biosimilar-medicines
2024-01-26T15:38:07+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-takes-home-3-times-gold-2023-generics-bulletin-awards-sandoz-wins-company-year-leader-year
2024-01-26T15:37:45+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-first-company-achieve-independent-certification-steps-minimize-risk-amr
2023-11-06T07:29:42+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-successfully-issues-eur-20-billion-inaugural-eurobonds
2023-11-08T17:53:53+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-inaugurates-new-antibiotic-production-plant-austria-and-new-biosimilar-development-center
2023-11-10T20:16:24+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/report-hundreds-thousands-patients-across-europe-miss-out-advanced-medicines-due-low-biosimilar
2023-11-16T07:07:58+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-launches-hyrimozr-adalimumab-high-concentration-formulation-europe-aiming-improve-patient
2023-11-21T10:26:17+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-agreement-acquire-cimerlir-business-coherus-strengthening-position-us-market
2024-01-22T06:03:27+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-signs-science-based-targets-initiative-sbti-commitment-letter
2024-01-30T08:29:09+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-launches-first-and-only-biosimilar-multiple-sclerosis-tyrukor-natalizumab-germany
2024-01-31T06:10:57+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-changes-board-directors
2024-02-01T06:16:58+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-us-subsidiaries-resolve-generic-drug-antitrust-class-action-litigation-direct-purchaser
2024-02-29T06:03:30+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-and-global-generics-industry-call-bold-coordinated-global-action-ensure-sustainability
2024-03-01T10:05:49+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-acquires-cimerlir-business-coherus-further-building-biosimilar-and-ophthalmology-leadership
2024-03-04T06:21:17+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-announces-nominations-board-directors-and-leadership-change
2024-03-05T06:02:16+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-receives-fda-approval-first-and-only-denosumab-biosimilars
2024-03-05T20:53:10+00:00
yearly
0.5
https://www.sandoz.comhttp://spare53_sandoz_com/sandoz-reports-fourth-quarter-2023-sales-and-full-year-2023-results
2024-03-13T07:20:06+00:00
yearly
0.5